|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group, : Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al
RESORCE Investigators, : Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): A randomised, double-blind, placebo-controlled, phase 3
trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al IMbrave150
investigators, : Atezolizumab plus bevacizumab in unresectable
hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abou-Elella A, Gramlich T, Fritsch C and
Gansler T: c-myc amplification in hepatocellular carcinoma predicts
unfavorable prognosis. Mod Pathol. 9:95–98. 1996.PubMed/NCBI
|
|
8
|
Schaub FX, Dhankani V, Berger AC, Trivedi
M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, et al
Cancer Genome Atlas Network, : Pan-cancer alterations of the MYC
oncogene and its proximal network across the Cancer Genome Atlas.
Cell Syst. 6:282–300.e2. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duffy MJ and Crown J: Drugging
‘undruggable’ genes for cancer treatment: Are we making progress?
Int J Cancer. 148:8–17. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Massó-Vallés D and Soucek L: Blocking Myc
to treat cancer: Reflecting on two decades of omomyc. Cells.
9:8832020. View Article : Google Scholar
|
|
11
|
Hubert RS, Vivanco I, Chen E, Rastegar S,
Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, et
al: STEAP: A prostate-specific cell-surface antigen highly
expressed in human prostate tumors. Proc Natl Acad Sci USA.
96:14523–14528. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moreaux J, Kassambara A, Hose D and Klein
B: STEAP1 is overexpressed in cancers: A promising therapeutic
target. Biochem Biophys Res Commun. 429:148–155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gomes IM, Maia CJ and Santos CR: STEAP
proteins: From structure to applications in cancer therapy. Mol
Cancer Res. 10:573–587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oosterheert W and Gros P: Cryo-electron
microscopy structure and potential enzymatic function of human
six-transmembrane epithelial antigen of the prostate 1 (STEAP1). J
Biol Chem. 295:9502–9512. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura H, Takada K, Arihara Y, Hayasaka
N, Murase K, Iyama S, Kobune M, Miyanishi K and Kato J:
Six-transmembrane epithelial antigen of the prostate 1 protects
against increased oxidative stress via a nuclear erythroid
2-related factor pathway in colorectal cancer. Cancer Gene Ther.
26:313–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Menyhárt O, Nagy Á and Győrffy B:
Determining consistent prognostic biomarkers of overall survival
and vascular invasion in hepatocellular carcinoma. R Soc Open Sci.
5:1810062018. View Article : Google Scholar
|
|
17
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mani M, Carrasco DE, Zhang Y, Takada K,
Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V,
Bertagnolli M, et al: BCL9 promotes tumor progression by conferring
enhanced proliferative, metastatic, and angiogenic properties to
cancer cells. Cancer Res. 69:7577–7586. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao
JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, Horst D, et al:
Targeted disruption of the BCL9/β-catenin complex inhibits
oncogenic Wnt signaling. Sci Transl Med. 4:148ra1172012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayasaka N, Takada K, Nakamura H, Arihara
Y, Kawano Y, Osuga T, Murase K, Kikuchi S, Iyama S, Emori M, et al:
Combination of eribulin plus AKT inhibitor evokes synergistic
cytotoxicity in soft tissue sarcoma cells. Sci Rep. 9:57592019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsuoka K, Koreth J, Kim HT, Bascug G,
McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, et al:
Low-dose interleukin-2 therapy restores regulatory T cell
homeostasis in patients with chronic graft-versus-host disease. Sci
Transl Med. 5:179ra432013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Llovet JM, Montal R, Sia D and Finn RS:
Molecular therapies and precision medicine for hepatocellular
carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Danila DC, Szmulewitz RZ, Vaishampayan U,
Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang
B, Kabbarah O, et al: Phase I study of DSTP3086S, an antibody-drug
conjugate targeting six-transmembrane epithelial antigen of
prostate 1, in metastatic castration-resistant prostate cancer. J
Clin Oncol. 37:3518–3527. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dolezal JM, Wang H, Kulkarni S, Jackson L,
Lu J, Ranganathan S, Goetzman ES, Bharathi SS, Beezhold K,
Byersdorfer CA, et al: Sequential adaptive changes in a
c-Myc-driven model of hepatocellular carcinoma. J Biol Chem.
292:10068–10086. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng K, Cubero FJ and Nevzorova YA:
c-MYC-making liver sick: Role of c-MYC in hepatic cell function,
homeostasis and disease. Genes (Basel). 8:1232017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grunewald TG, Diebold I, Esposito I, Plehm
S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R,
Müller-Tidow C, et al: STEAP1 is associated with the invasive and
oxidative stress phenotype of Ewing tumors. Mol Cancer Res.
10:52–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
